文献速递浆细胞疾病

口服伊沙佐米联合来那度胺地塞米松治疗不适合移植的新诊断多发性骨髓瘤

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
PubMed 文献 · Blood · 2021-01-01

TOURMALINE-MM2双盲安慰剂对照试验纳入不适合移植的新诊断多发性骨髓瘤患者,随机接受伊沙佐米或安慰剂联合来那度胺-地塞米松治疗。加用伊沙佐米耐受性可接受,无新安全信号,为特定患者提供全口服三联方案选择。

要点

  • 伊沙佐米组完全缓解率26% vs 14%,≥非常好的部分缓解率63% vs 48%,均显著提高。

核心结论

  • 在不适合移植的新诊断多发性骨髓瘤患者中,伊沙佐米联合来那度胺-地塞米松较安慰剂联合方案延长中位PFS 13.5个月,但主要终点未达统计学显著。
  • 加用伊沙佐米耐受性可接受,无新安全信号,全口服三联方案为特定患者提供可行选择。

研究设计与样本

  • 双盲、安慰剂对照的TOURMALINE-MM2试验,纳入不适合移植的新诊断多发性骨髓瘤患者。
  • 患者随机接受伊沙佐米4 mg(n=351)或安慰剂(n=354)联合来那度胺-地塞米松治疗。
  • 18个周期后停用地塞米松,继续减量伊沙佐米3 mg和来那度胺10 mg直至疾病进展或毒性。
  • 主要终点为无进展生存期(PFS)。

主要发现

  • 总体治疗中出现的不良事件大多为1/2级。
  • 伊沙佐米组 vs 安慰剂组:≥3级不良事件88% vs 81%,严重不良事件66% vs 62%,导致方案中止的不良事件35% vs 27%,研究期间死亡8% vs 6%。

关键数值与推荐

  • 伊沙佐米4 mg联合来那度胺-地塞米松方案,18周期后减量为伊沙佐米3 mg和来那度胺10 mg持续治疗。

临床怎么用

  • 伊沙佐米联合来那度胺-地塞米松可作为不适合移植的新诊断多发性骨髓瘤患者的全口服三联方案选择。
  • 尤其适用于可从全口服方案获益的特定患者,需权衡PFS获益与不良反应及停药风险。

局限性

  • ≥3级不良事件、严重不良事件及导致方案中止的不良事件在伊沙佐米组均高于安慰剂组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Continuous lenalidomide-dexamethasone (Rd)-based regimens are among the standards of care in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. The oral proteasome inhibitor ixazomib is suitable for continuous dosing, with predictable, manageable toxicities. In the double-blind, placebo-controlled TOURMALINE-MM2 trial, transplant-ineligible NDMM patients were randomized to ixazomib 4 mg (n = 351) or placebo (n = 354) plus Rd. After 18 cycles, dexamethasone was discontinued and treatment was continued using reduced-dose ixazomib (3 mg) and lenalidomide (10 mg) until progression/toxicity. The primary endpoint was progression-free survival (PFS). Median PFS was 35.3 vs 21.8 months with ixazomib-Rd vs placebo-Rd, respectively (hazard ratio [HR], 0.830; 95% confidence interval, 0.676-1.018; P = .073; median follow-up, 53.3 and 55.8 months). Complete (26% vs 14%; odds ratio [OR], 2.10; P < .001) and ≥ very good partial response (63% vs 48%; OR, 1.87; P < .001) rates were higher with ixazomib-Rd vs placebo-Rd. In a prespecified high-risk cytogenetics subgroup, median PFS was 23.8 vs 18.0 months (HR, 0.690; P = .019). Overall, treatment-emergent adverse events (TEAEs) were mostly grade 1/2. With ixazomib-Rd vs placebo-Rd, 88% vs 81% of patients experienced grade ≥3 TEAEs, 66% vs 62% serious TEAEs, and 35% vs 27% TEAEs resulting in regimen discontinuation; 8% vs 6% died on study. Addition of ixazomib to Rd was tolerable with no new safety signals and led to a clinically meaningful PFS benefit of 13.5 months. Ixazomib-Rd is a feasible option for certain patients who can benefit from an all-oral triplet combination. This trial was registered at www.clinicaltrials.gov as #NCT01850524.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021. PMID: 33763699. doi:10.1182/blood.2020008787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。